GARDASIL®: Prophylactic human papillomavirus vaccine development - From bench top to bed-side

Clinical Pharmacology and Therapeutics

Volumn 81, Issue 2, 2007, Pages 259-264

  Shi, Li ^a   Sings, H L ^a   Bryan, J T ^a   Wang, B ^a   Wang, Y ^a   Mach, H ^a   Kosinski, M ^a   Washabaugh, M W ^a   Sitrin, R ^a   Barr, E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18; PAPILLOMA VIRUS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ARTICLE; CANCER SCREENING; CERCOPITHECIDAE; COLPOSCOPY; CONDYLOMA; DISEASE SEVERITY; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG STABILITY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; IN VIVO STUDY; INFECTION PREVENTION; NONHUMAN; PERSISTENT VIRUS INFECTION; POINT OF CARE TESTING; PRIORITY JOURNAL; RADIOIMMUNOASSAY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERUS BIOPSY; VAGINA DISEASE; VIRUS PARTICLE; VULVA DISEASE; WART VIRUS; ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; ANIMAL; CHILD; CLINICAL TRIAL; DRUG SCREENING; FEMALE; IMMUNOLOGY; METHODOLOGY; REVIEW; VIROLOGY; VIRUS INFECTION;

ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; ANIMALS; CHILD; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 33846647567     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100055     Document Type: Article

References (21)

1. Mach, H. et al. Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs). J. Pharm. Sci. 95, 2195-2206 (2006).
2. Palker, T.J. et al. Antibody cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles. Vaccine 19, 3733-3743 (2001).
3. Mao, C. et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol. 107, 18-27 (2006).
4. Villa, L.L. et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6, 271-278 (2005).
5. Sattler, C. Efficacy of a prophylactic quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine for prevention of cervical dysplasia and external genital lesions (EGL). [Abstract LB2-25] In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, December 16-19, 2005 (American Society for Microbiology, Washington, DC, 2005).
6. Skjeldestad, F.E. Prophylactic quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine (Gardasil™) reduces cervical intraepithelial neoplasia (CIN) 2/3 Risk [Abstract LB-8a] In: 43rd Infectious Diseases Society of America, San Francisco, CA, October 5 to 9, 2005 (Infectious Diseases Society of America, Alexandria, VA, 2005).
7. Villa, L.L. et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Brit. J. Cancer 95, 1459-1466 (2006).
8. Block, S. et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6,11,16,18) L1 virus-like particle (VLP) vaccine in male and female adolescents and young adult women. Pediatrics 118, 2135-2145 (2006).
9. Parkin, D.M. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118, 3030-3044 (2006).
10. Vaccines against human papillomavirus World Health Organization [web site]. Available at: http://www.who.int/vaccines/en/hpvrd.shtml/ shtml. Accessed July 12, 2004.
11. CDC. Genital HPV infection. Genital HPV Infection [web site]. Available at: http://www.cdc.giv/std/HPV/STDFact-HPV.html. Accessed September 21, 2004.
12. Ferlay, J., Bray, F., Pisani, P. & Parkin, D.M. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No.5, Version 2.0, IARC Press. Available at: www-epdb.iarc.fr/globocan/ GLOBOCAN2002.HTM. Accessed March 15, 2005.
13. Pratt, D., Goldenthal, K. & Gerber, A. Preventative human papillomavirus (HPV) vaccines - regulatory breifing documents on endpoints V. 2001. Vaccines and Related Biological Products Advisory Committe Meeting, November 28-28.
14. Pagliusi, S.R. & Aguado, T.A. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 23, 569-578 (2004).
15. Li, M., Cripe, T.P., Estes, P.A., Lyon, M.K., Rose, R.C. & Garcea, R.L. Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly. J. Virol. 71, 2988-2995 (1997).
16. Zhou, J., Sun, X.Y., Stenzel, D.J. & Frazer, I.H. Expression of vaccina recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185, 251-257 (1991).
17. Koutsky, L.A. et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347, 1645-1651 (2002).
18. Cook, J.C. et al. Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae. Protein Expression. Purif. 17, 477-484 (1999).
19. Shi, L. et al. Stabilization of human papillomavirus virus-like particles by non-ionic surfactants. J. Pharm. Sci. 94, 1538-1551 (2005).
20. Retzlaff, M. et al. Evaluation of the thermal stability of GARDASIL®. Human Vaccines 2, 147-154 (2006).
21. Ruiz, W., McClements, W.L., Jansen, K.U. & Esser, M.T. Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant. J. Immune. Based Ther. Vaccines 3, 2 (2005).